{"id":"ergometrine","rwe":[{"pmid":"41844474","year":"2026","title":"Uterotonics in pregnant patients with cardiac disease: a focused review.","finding":"","journal":"International journal of obstetric anesthesia","studyType":"Clinical Study"},{"pmid":"41485826","year":"2026","title":"Management of immediate and delayed postpartum hemorrhage with cesarean delivery.","finding":"","journal":"American journal of obstetrics and gynecology","studyType":"Clinical Study"},{"pmid":"41436225","year":"2025","title":"Takotsubo cardiomyopathy following ergometrine administration during caesarean section.","finding":"","journal":"BMJ case reports","studyType":"Clinical Study"},{"pmid":"41078143","year":"2026","title":"One dose, big impact: Revisiting carbetocin in high-risk polyhydramnios deliveries.","finding":"","journal":"International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics","studyType":"Clinical Study"},{"pmid":"40732298","year":"2025","title":"Effects of Psilocin and Psilocybin on Human 5-HT(4) Serotonin and H(2) Histamine Receptors in Perfused Hearts of Transgenic Mice.","finding":"","journal":"Pharmaceuticals (Basel, Switzerland)","studyType":"Clinical Study"}],"tags":[{"label":"ergometrine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"5-hydroxytryptamine receptor 1D","category":"target"},{"label":"HTR1D","category":"gene"},{"label":"HTR6","category":"gene"},{"label":"HTR2B","category":"gene"},{"label":"G02AB03","category":"atc"},{"label":"Active","category":"status"},{"label":"Postabortal Hemorrhage","category":"indication"},{"label":"Postpartum hemorrhage","category":"indication"},{"label":"Cairo University","category":"company"},{"label":"Oxytocics","category":"pharmacology"},{"label":"Reproductive Control Agents","category":"pharmacology"}],"phase":"marketed","safety":{"contraindications":["Arteriosclerosis obliterans","Cerebrovascular accident","Disease of liver","Hypertensive disorder","Kidney disease","Pregnancy, function","Pregnancy-induced hypertension","Seizure disorder","Sepsis syndrome"]},"trials":[],"aliases":["Mitrotan","Active Comparator"],"company":"Cairo University","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Ergometrine","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:49:19.788728+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Ergometrine","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:49:28.754177+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:49:27.256347+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ergometrine","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:49:28.168613+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL119443/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:49:28.641367+00:00"}},"allNames":"ergobasine","offLabel":[],"synonyms":["ergonovine maleate","ergometrine maleate","ergometrine","ergonovine","ergometrin","ergostetrine","ergotocine","ergobasine"],"timeline":[],"approvals":[],"brandName":"Ergobasine","ecosystem":[{"indication":"Postabortal Hemorrhage","otherDrugs":[{"name":"methylergometrine","slug":"methylergometrine","company":"Edison Theraps Llc"}],"globalPrevalence":null},{"indication":"Postpartum hemorrhage","otherDrugs":[{"name":"carboprost","slug":"carboprost","company":"Pharmacia And Upjohn"},{"name":"methylergometrine","slug":"methylergometrine","company":"Edison Theraps Llc"},{"name":"misoprostol","slug":"misoprostol","company":"Gd Searle Llc"},{"name":"oxytocin","slug":"oxytocin","company":"Novartis"}],"globalPrevalence":null}],"mechanism":{"target":"5-hydroxytryptamine receptor 1D","targets":[{"gene":"HTR1D","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1D","protein":"5-hydroxytryptamine receptor 1D"},{"gene":"HTR6","source":"DrugCentral","target":"5-hydroxytryptamine receptor 6","protein":"5-hydroxytryptamine receptor 6"},{"gene":"HTR2B","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2B","protein":"5-hydroxytryptamine receptor 2B"},{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"},{"gene":"HTR1A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1A","protein":"5-hydroxytryptamine receptor 1A"},{"gene":"DRD2","source":"DrugCentral","target":"D(2) dopamine receptor","protein":"D(2) dopamine receptor"},{"gene":"HTR2C","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2C","protein":"5-hydroxytryptamine receptor 2C"},{"gene":"HTR1E","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1E","protein":"5-hydroxytryptamine receptor 1E"},{"gene":"ADRA2B","source":"DrugCentral","target":"Alpha-2B adrenergic receptor","protein":"Alpha-2B adrenergic receptor"},{"gene":"DRD3","source":"DrugCentral","target":"D(3) dopamine receptor","protein":"D(3) dopamine receptor"}],"modality":"Small Molecule","drugClass":"ergometrine","explanation":"","oneSentence":"","technicalDetail":"Ergobasine exerts its effects by activating the 5-HT1D receptor, a subtype of serotonin receptor, which is involved in the regulation of vascular tone and platelet aggregation."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Ergonovine","title":"Ergonovine","extract":"Ergonovine, also known as ergometrine and lysergic acid propanolamide, is a medication used to cause contractions of the uterus to treat heavy vaginal bleeding after childbirth. It can be used either by mouth, by injection into a muscle, or injection into a vein.","wiki_history":"==History==\nThe pharmacological properties of ergot were known and had been utilized by midwives for centuries, but were not thoroughly researched and publicized until the early 20th century. However, its abortifacient effects and the danger of ergotism meant that it was only prescribed cautiously, as in the treatment of postpartum haemorrhage.\n\nErgonovine was first isolated and obtained by the chemists C Moir, H W Dudley and Gerald Rogers in 1935. Caroline De Costa has argued that the adoption of ergonovine for preventive use and for treating bleeding contributed to the decline in the maternal mortality rate in much of the West during the early 20th century.","wiki_society_and_culture":"==Society and culture==\n===Recreational use===\nErgonovine induces hallucinogenic effects at doses of 2–10mg, in contrast to its medical use in doses of 0.2–0.4mg. The most common source of ergonovine for drug users is Ipomoea tricolor seeds, as they are the only commonly available natural product that hosts an ergoline-generating fungus. The ergonovine content of I. tricolor seeds varies between one-tenth and one-third of ergine, an ergonovine analog. One person who had the opportunity to try ergonovine to see its psychedelic potential stated that it was mild relative to other psychedelics, but that ergine may synergize with it; indeed the contrast between Hofmann's self-administration of Ipomoea corymbosa extract and synthetic ergine is apparent in his essay on the initial analysis of I. corymbosa and I. tricolor seeds. It is also regulated in the United States. As an N-alkyl derivative of ergine, ergonovine is covered by the Misuse of Drugs Act 1971, effectively rendering it illegal in the United Kingdom as well."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1042","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=Ergometrine","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ergometrine","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Ergonovine","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T11:06:05.608478","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:49:30.532076+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"methylergometrine","drugSlug":"methylergometrine","fdaApproval":"1946-11-19","relationship":"same-class"}],"genericName":"ergometrine","indications":{"approved":[{"name":"Postabortal Hemorrhage","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Postpartum hemorrhage","source":"DrugCentral","snomedId":47821001,"regulator":"FDA"}],"offLabel":[{"name":"Incomplete miscarriage","source":"DrugCentral","drugName":"Ergometrine","evidenceCount":7,"evidenceLevel":"emerging"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"methylergometrine","brandName":"methylergometrine","genericName":"methylergometrine","approvalYear":"1946","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07390864","phase":"NA","title":"Ergometrine Versus Carbetocin to Decrease Blood Loss in Myomectomy","status":"RECRUITING","sponsor":"Cairo University","startDate":"2026-01-18","conditions":["Myoma;Uterus"],"enrollment":40,"completionDate":"2026-08-30"},{"nctId":"NCT03584854","phase":"PHASE4","title":"Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2019-03-01","conditions":["Postpartum Hemorrhage","Uterine Atony"],"enrollment":100,"completionDate":"2022-06-15"},{"nctId":"NCT05772156","phase":"PHASE4","title":"Prophylactic Methylergonovine for Twin Cesarean","status":"COMPLETED","sponsor":"Columbia University","startDate":"2023-03-07","conditions":["Twin; Complicating Pregnancy","Postpartum Hemorrhage"],"enrollment":66,"completionDate":"2024-03-11"},{"nctId":"NCT06285409","phase":"NA","title":"Comparing the Dose-response Profiles of Uterotonics After Initial Carbetocin Administration - an Ex-vivo Study in Desensitized Human Myometrium","status":"RECRUITING","sponsor":"Samuel Lunenfeld Research Institute, Mount Sinai Hospital","startDate":"2024-04-04","conditions":["Postpartum Hemorrhage"],"enrollment":32,"completionDate":"2025-12"},{"nctId":"NCT03390010","phase":"PHASE1","title":"Misoprostol Versus Active Management of Labour in CS","status":"COMPLETED","sponsor":"Aljazeera Hospital","startDate":"2017-12-28","conditions":["Cesarean Section"],"enrollment":300,"completionDate":"2018-03-06"},{"nctId":"NCT03904446","phase":"PHASE4","title":"Multimodal Uterotonics at the Time of Cesarean Section in Laboring Patients","status":"COMPLETED","sponsor":"Cynthia Wong","startDate":"2019-06-08","conditions":["Uterine Atony With Hemorrhage"],"enrollment":160,"completionDate":"2021-02-15"},{"nctId":"NCT05099575","phase":"","title":"Protocols for Prevention of PPH During CS in High Risk Group","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2021-10-30","conditions":["Atonic PPH"],"enrollment":448,"completionDate":"2022-10-30"},{"nctId":"NCT02044549","phase":"PHASE4","title":"Carbetocin Versus Syntometrine for Prevention of Postpartum Hemorrhage After Cesarean Section","status":"COMPLETED","sponsor":"Cairo University","startDate":"2014-06","conditions":["Postpartum Hemorrhage","Blood Loss"],"enrollment":300,"completionDate":"2015-12"},{"nctId":"NCT02046499","phase":"NA","title":"A Randomized Trial Comparing Oxytocin and Oxytocin + Ergometrine for Prevention of Postpartum Haemorrhage at Caesarean Section","status":"COMPLETED","sponsor":"University of Pretoria","startDate":"2014-01-01","conditions":["Prevention of Post Partum Haemorrhage"],"enrollment":540,"completionDate":"2014-09-30"},{"nctId":"NCT01869556","phase":"NA","title":"Comparison of IV Ergonovine With IM Carboprost, With Oxytocin IV, During Cesarean Section for Failure to Progress","status":"COMPLETED","sponsor":"Samuel Lunenfeld Research Institute, Mount Sinai Hospital","startDate":"2013-06-04","conditions":["Postpartum Hemorrhage"],"enrollment":105,"completionDate":"2019-09-30"},{"nctId":"NCT03578263","phase":"NA","title":"Carbetocin Versus Oxytocin and Ergometrine for the Prevention of Postpartum Hemorrhage","status":"COMPLETED","sponsor":"Aswan University Hospital","startDate":"2018-04-01","conditions":["Cesarean Section Complications"],"enrollment":220,"completionDate":"2020-08-01"},{"nctId":"NCT03570671","phase":"NA","title":"Noninvasive Cardiac Imaging in Vasospastic Angina Korean Registry (NAVIGATOR)","status":"UNKNOWN","sponsor":"Dong-A University","startDate":"2018-03-01","conditions":["Spasm"],"enrollment":90,"completionDate":"2021-07-01"},{"nctId":"NCT03303235","phase":"EARLY_PHASE1","title":"Intravenous Versus Intramuscular Administration of Methylergonovine for Uterine Contraction in Cesarean Sections","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2020-07","conditions":["Uterine Atony","Uterine Tone Disorders","Postpartum Hemorrhage"],"enrollment":0,"completionDate":"2020-12"},{"nctId":"NCT02180971","phase":"NA","title":"Multidetector Coronary CT In Vasospastic Angina","status":"UNKNOWN","sponsor":"Dong-A University","startDate":"2014-04","conditions":["Vasospastic Angina"],"enrollment":150,"completionDate":"2021-03"},{"nctId":"NCT04300452","phase":"PHASE4","title":"Carbetocin Versus Ergometrin in the Prevention of Postpartum Hemorrhage","status":"UNKNOWN","sponsor":"National and Kapodistrian University of Athens","startDate":"2018-04-05","conditions":["Postpartum Hemorrhage"],"enrollment":100,"completionDate":"2020-09-30"},{"nctId":"NCT03693599","phase":"PHASE4","title":"Carbetocin Versus Syntometrine in Obese Women Undergoing Elective Cesarean","status":"COMPLETED","sponsor":"Cairo University","startDate":"2018-10-01","conditions":["Post Partum Hemorrhage"],"enrollment":1200,"completionDate":"2019-09-30"},{"nctId":"NCT02408965","phase":"PHASE4","title":"Uterotonic Prophylaxis Trial","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2015-03","conditions":["Hemorrhage"],"enrollment":284,"completionDate":"2017-03"},{"nctId":"NCT01549223","phase":"PHASE4","title":"Oxytocin And Uterotonic Agent Use For Cesarean Delivery","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2011-04","conditions":["Uterine Atony","Hypotension"],"enrollment":60,"completionDate":"2012-01"},{"nctId":"NCT02306733","phase":"PHASE3","title":"Ergometrine Versus Oxytocin in the Management of Atonic Post-partum Haemorrhage (PPH) in Women Delivered Vaginally","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2014-11","conditions":["Post Partum Hemorrhage"],"enrollment":200,"completionDate":""},{"nctId":"NCT02410759","phase":"PHASE3","title":"Carbetocin Versus Ergometrine in the Management of Atonic Post Partum Haemorrhage (PPH) in Women Delivered Vaginally","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2015-04","conditions":["Post Partum Hemorrhage"],"enrollment":200,"completionDate":""},{"nctId":"NCT02101567","phase":"PHASE4","title":"Carbetocin Versus Oxytocin and Ergometrine for the Prevention of Postpartum Haemorrhage Following Caesarean Section","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2014-05","conditions":["Bleeding","Anemia"],"enrollment":200,"completionDate":"2015-04"},{"nctId":"NCT00989027","phase":"NA","title":"Impact of Uterotonic Agents on Isolated Human Myometrium","status":"COMPLETED","sponsor":"Samuel Lunenfeld Research Institute, Mount Sinai Hospital","startDate":"2007-06","conditions":["Postpartum Hemorrhage"],"enrollment":56,"completionDate":"2013-08"},{"nctId":"NCT01689311","phase":"NA","title":"In Vitro Myometrial Contractions in Laboring and Non-laboring Women","status":"COMPLETED","sponsor":"Samuel Lunenfeld Research Institute, Mount Sinai Hospital","startDate":"2009-03","conditions":["Postpartum Hemorrhage"],"enrollment":53,"completionDate":"2012-08"},{"nctId":"NCT00858832","phase":"NA","title":"Reduction of Endometritis After Cesarean Section With the Routine Use of Methergine","status":"COMPLETED","sponsor":"University of South Florida","startDate":"2008-12","conditions":["Endometritis"],"enrollment":44,"completionDate":"2011-01"},{"nctId":"NCT00707928","phase":"PHASE4","title":"Intravenous Nitroglycerin for Retained Placenta Extraction: a Multicenter Study","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2008-02","conditions":["Retained Placenta"],"enrollment":100,"completionDate":"2010-12"},{"nctId":"NCT01236482","phase":"PHASE4","title":"Oxytocin in Cesarean Delivery","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"2010-11","conditions":["Post Partum Hemorrhage"],"enrollment":80,"completionDate":"2011-05"},{"nctId":"NCT00481533","phase":"NA","title":"Ergot and Oxytocin During Cesarean Delivery Following Failure to Progress in Labour","status":"COMPLETED","sponsor":"Samuel Lunenfeld Research Institute, Mount Sinai Hospital","startDate":"2005-06","conditions":["Blood Loss, Surgical"],"enrollment":47,"completionDate":"2007-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000179118","MMSL":"3591","NDDF":"001305","UNII":"YMH3D0ZJWV","VUID":"4017426","CHEBI":"CHEBI:4822","VANDF":"4017426","INN_ID":"390","RXNORM":"24313","UMLSCUI":"C0014704","chemblId":"CHEMBL119443","ChEMBL_ID":"CHEMBL119443","KEGG_DRUG":"D01163","DRUGBANK_ID":"DB01253","PUBCHEM_CID":"443884","SNOMEDCT_US":"126071000","IUPHAR_LIGAND_ID":"148","SECONDARY_CAS_RN":"129-51-1","MESH_DESCRIPTOR_UI":"D004874"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Cairo University","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"50%"},"publicationCount":636,"therapeuticAreas":["Hematology"],"atcClassification":{"source":"DrugCentral","atcCode":"G02AB03","allCodes":["G02AB03"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 6","pmid":"41844474","title":"Uterotonics in pregnant patients with cardiac disease: a focused review.","journal":"International journal of obstetric anesthesia"},{"date":"2026 Jan","pmid":"41485826","title":"Management of immediate and delayed postpartum hemorrhage with cesarean delivery.","journal":"American journal of obstetrics and gynecology"},{"date":"2025 Dec 23","pmid":"41436225","title":"Takotsubo cardiomyopathy following ergometrine administration during caesarean section.","journal":"BMJ case reports"},{"date":"2026 Apr","pmid":"41078143","title":"One dose, big impact: Revisiting carbetocin in high-risk polyhydramnios deliveries.","journal":"International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics"},{"date":"2025 Jul 6","pmid":"40732298","title":"Effects of Psilocin and Psilocybin on Human 5-HT(4) Serotonin and H(2) Histamine Receptors in Perfused Hearts of Transgenic Mice.","journal":"Pharmaceuticals (Basel, Switzerland)"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Cairo University","companyId":"cairo-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:49:30.532076+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}